Moderna accelerates timeline for delivery of COVAX vaccines
Includes 20 million more doses by the end of the 2021
Moderna announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million Covid-19 doses to COVAX by Dec. 31, for a total of 54 million doses made available to COVAX in 2021. Deliveries to the 92 COVAX Advance Market Commitment (AMC) countries are underway.
These doses are included in Moderna’s previously announced agreement with Gavi and were originally scheduled for delivery in Q1 of 2022. The biotech company now expects to supply up to 96.5 million doses in Q1 of 2022, and an additional 116.5 million doses in Q2 of 2022. Per the original agreement, Gavi also retains the option to acquire 233 million additional doses in 2022.
Additionally, Moderna is announcing a new supply agreement with Gavi for an additional 20 million doses for delivery in Q2 of 2022, for a total of up to 136.5 million doses in that quarter. Gavi retains options to purchase an additional 30 million doses in the Q2, and 100 million more doses in the Q3 of next year. Together, these two agreements allow Gavi to purchase up to 650 million doses of the Moderna Covid vaccine for delivery through 2022.
